Effect of Bosweilia Serrata in treatment of Mild cognitive dementia (MCI)

Comparison between treatment with Bosweilia Serrata versus placebo in improving Mild cognitive dementia (MCI)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201402088430N8

Enrollment

Registered

2015-03-12

Start date

2014-06-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dementia NOS. unclassified dementia

Interventions

Intervention 1: "Intervention group" : capsule Bosweilia, 300mg, BID , 3 months. Intervention 2: "Control group" : capsule placebo, BID ,3months.

Treatment - Drugs

"Intervention group" : capsule Bosweilia, 300mg, BID , 3 months

"Control group" : capsule placebo, BID ,3months

Eligibility

Sex/Gender

All

Age

55 Years to 85 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Confirmation of MCI related to Peterson criterion; Lack of contraindication for taking Bosweili ; Points less than 7 in BECK test ; Normal brain MRI Exclusion criteria:Not MCI related to Peterson criterion; contraindication to taking Bosweili ; Points more than 7 in BECK test ;Abnormal brain MRI

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
MCI ( mild mental impairment ). Timepoint: Baseline & 3months after the intervention. Method of measurement: MOCA test.	—

Secondary

Measure	Time frame
Evaluation of improving MCI. Timepoint: After 3 months intervention. Method of measurement: MOCA test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKave Shafii

Kerman University of Medical Sciences and Heaith Services

shafahospital@kmu.ac.ir+98 34 3211 5780

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026